Protara Therapeutics reported a net loss of $21.7 million, or $0.36 per share, for the second quarter ended June 30, 2026, compared to a $15.0 million loss in the prior-year period. Cash and investments totaled approximately $162 million as of June 30, 2026, which management expects will fund operations into 2028. The company provided clinical updates, including an expectation to complete enrollment of the BCG-Unresponsive cohort in the ADVANCED-2 trial by the fourth quarter of 2026 and a plan to submit a Biologics License Application for TARA-002 in Lymphatic Malformations in the second half of 2027. Interim results from the THRIVE-3 registrational trial are also expected in the fourth quarter of 2026. Protara Therapeutics is a clinical-stage biotechnology company developing transformative therapies for cancer and rare diseases.